ARCHIMED moves to take Esperion private in $1.1B deal

ARCHIMED, a healthcare-focused investment firm, has agreed to acquire Esperion Therapeutics in a take-private deal valued at up to about $1.1 billion, according to Esperion’s May 1, 2026 announcement and related SEC filing. Esperion shareholders would receive $3.16 per share in cash at closing, plus non-tradeable contingent value rights tied to future U.S. sales of the company’s bempedoic acid products, NEXLETOL and NEXLIZET, and bumetanide nasal spray ENBUMYST. Esperion’s board unanimously approved the transaction, which is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals. (nasdaq.com)

Why it matters: For veterinary professionals, this is mainly a capital-markets signal rather than an animal health development. Still, it’s a useful reminder that private equity continues to target commercial-stage biopharma companies with marketed products, especially those with specialty and primary care growth potential. Esperion has been building a broader cardiometabolic franchise, including its April 2026 acquisition of Corstasis and ENBUMYST, so the deal suggests ARCHIMED sees room to grow those assets outside the pressures of the public market. (esperion.gcs-web.com)

What to watch: Watch for Esperion’s proxy filing, shareholder vote, and whether regulators clear the transaction on the company’s expected third-quarter 2026 timeline. (sec.gov)